Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Acetic Acid Clear all
Recruiting Phase 3 Interventional

ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3

NCT06716021
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Placebo, Etripamil
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
West Hills, California • Littleton, Colorado • Haddon Heights, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?

NCT01964118
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Intermittent Fasting group, control group
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
30 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

NCT01723020
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Glioblastoma, Multiple Myeloma
Interventions
AMG 232
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
9
States / cities
Santa Monica, California • Norwalk, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

NCT04502394
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Interventions
KRT-232, acalabrutinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Goshen, Indiana • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT02157506
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Acute Heart Failure
Interventions
CXL-1427, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Gainesville, Florida • Jacksonville, Florida • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Phase 1 Interventional

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2

NCT03332355
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
PAC-1 Compound
Drug
Lead sponsor
Vanquish Oncology, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Baltimore, Maryland • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Chelation Therapy 2

NCT02733185
View directory record Official record
Conditions
Diabetes, Myocardial Infarction
Interventions
disodium EDTA, Oral Multi Vitamins/Minerals (OMVM), Placebo disodium EDTA, Placebo Oral Multi Vitamins/Minerals (OMVM)
Drug · Dietary Supplement
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 21, 2026, 10:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Study of Effect of Vaginal ph and Acidification of Vaginal Misoprostol on Its Efficacy for Induction of Midtrimester Abortion

NCT01241045
View directory record Official record
Conditions
To Evaluate the Impact of the Vaginal Ph and Acidification of Vaginal Misoprostol on Its Efficacy in Facilitating Induction of Mid-trimester Abortion.
Interventions
Not listed
Lead sponsor
Ain Shams University
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cairo, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 21, 2026, 10:53 PM EDT
Not listed Phase 1Phase 2 Interventional

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

NCT04669067
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
TL-895, KRT-232
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

NCT00551148
View directory record Official record
Conditions
Primary Insomnia
Interventions
PD 0200390, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
16
States / cities
Glendale, Arizona • Phenoix, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits

NCT05523115
View directory record Official record
Conditions
Anxiety, Stress, Memory Deficits, Cortisol Overproduction
Interventions
Heights Smart Supplement
Dietary Supplement
Lead sponsor
Heights
Industry
Eligibility
21 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Daily Vinegar Ingestion and Metabolic Health

NCT05698381
View directory record Official record
Conditions
Inflammation, Metabolic Syndrome, Depression
Interventions
Liquid vinegar, Vinegar pill
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Daily Vinegar Ingestion for Four Weeks on Mood State in Healthy College Students

NCT04706806
View directory record Official record
Conditions
Mood, Depression
Interventions
apple cider vinegar, vinegar pill
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

NCT01173471
View directory record Official record
Conditions
Raised Intraocular Pressure
Interventions
AZD4017, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Newport Beach, California • Atlanta, Georgia • Morrow, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

A Low ChloridE hyperTonic Solution for Brain Edema

NCT03204955
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Acute Kidney Injury
Interventions
Sodium chloride /sodium acetate (16.4%), Sodium chloride (23.4%), PlasmaLyte
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

NCT02110355
View directory record Official record
Conditions
Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma
Interventions
AMG 232, Trametinib, Dabrafenib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)

NCT01521793
View directory record Official record
Conditions
LCA (Leber Congenital Amaurosis), RP (Retinitis Pigmentosa)
Interventions
QLT091001
Drug
Lead sponsor
QLT Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effective Treatments for Jellyfish Stings

NCT02015195
View directory record Official record
Conditions
Jellyfish Stings
Interventions
Acetic Acid (5%), Sodium Bicarbonate Slurry (50%), Papain Slurry (70%), Ammonia (10%), Lidocaine (4%), Isopropyl Alcohol (70%), Hot Tap Water (40 degrees Celsius), No treatment
Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

NCT00540722
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
R-(-)-gossypol acetic acid, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

NCT02016729
View directory record Official record
Conditions
Advanced Malignancy, Cancer, Oncology, Oncology Patients, Acute Myeloid Leukemia
Interventions
AMG 232, Trametinib
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Birmingham, Alabama • Buffalo, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia

NCT00263081
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment
Drug
Lead sponsor
Takeda
Industry
Eligibility
8 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 21, 2026, 10:53 PM EDT
Terminated Not applicable Interventional

The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis

NCT03775590
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Water, Bleach, Acetic acid
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Months to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 21, 2026, 10:53 PM EDT
Completed Phase 3 Interventional

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

NCT00143663
View directory record Official record
Conditions
Dyslipidemia
Interventions
Lapaquistat Acetate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
47
States / cities
Northport, Alabama • Mesa, Arizona • Chula Vista, California + 44 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Oct 21, 2026, 10:53 PM EDT